[go: up one dir, main page]

AP373A - Compounds having 5TH4 receptor antagonist activity. - Google Patents

Compounds having 5TH4 receptor antagonist activity. Download PDF

Info

Publication number
AP373A
AP373A APAP/P/1992/000422A AP9200422A AP373A AP 373 A AP373 A AP 373A AP 9200422 A AP9200422 A AP 9200422A AP 373 A AP373 A AP 373A
Authority
AP
ARIPO
Prior art keywords
hydrogen
alkyl
amino
benzodioxan
nmr
Prior art date
Application number
APAP/P/1992/000422A
Other versions
AP9200422A0 (en
Inventor
Francis David King
Laramie Mary Gaster
Keith Raymond Mulholland
Shirley Katherine Rahman
Paul Adrian Wyman
Gareth John Sanger
Kay Alison Wardle
Gordon Smith Baxter
Guy Anthony Kennet
Alberto Julio Kaumann
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919119692A external-priority patent/GB9119692D0/en
Priority claimed from GB929202510A external-priority patent/GB9202510D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP9200422A0 publication Critical patent/AP9200422A0/en
Application granted granted Critical
Publication of AP373A publication Critical patent/AP373A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of a compound of formula (1)or a pharmaceutically acceptable salt wherein the variables are defined in the specification, in the manufacture of a medicament for use in the treatment of gastrointestinal disorders, cardiovascular disoders and cns disorders.

Description

PHARMACEUTICALS
This invention relates to the use of compounds as 5-HT4 receptor 5 antagonists in the treatment of gastrointestinal disorders, CNS disorders and/or cardiovascular disorders, and to certain novel compounds having 5-HT4 receptor antagonist activity.
European Journal of Pharmacology 146 (1988), 187-188, and Naunyn10 Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non ( classical 5-hydroxytryptamine receptor, now designated the 5-HT4 receptor, and that ICS 205-930, which is also a 5-HT3 receptor antagonist,
C antagonises at this receptor.
Some 5-HT3 receptor antagonists have been disclosed as of potential use in the treatment of certain aspects of irritable bowel syndrome (see EP-A-189002 (Sandoz Limited) and EP-A-201165 (Beecham Group p.l.c)).
5-HT3 receptor interactions which are of potential use in the treatment of
IBS are those associated either with the visceral pain and abnormal perception of sensation aspects of this disease, or they are related to the ability of some 5-HT3 receptor antagonists to cause constipation in volunteers.
{ 25 Some 5-HT3 receptor antagonists have been disclosed as of potential use in the treatment of gastrointestinal disorders associated with upper gut motility [see EP-A-226266 (Glaxo Group Ltd.) and EP-A-189002 (Sandoz Limited)]. 5-HT3 receptor antagonists are also well known antiemetics, such as ondansetron, granisetron and tropisetron (see Drugs of the Future
1989, 14 (9) p.875 - F.D. King and G.J. Sanger).
PCT/GB91/00650 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT4 receptor antagonists in the treatment of atrial arrhythmias and stroke.
EP-A-36269 (Beecham Group p.l.c.) describes a group of compounds of potential use in the treatment of gastrointestinal motility disorders.
P30178
-2WO 92/10494 (Beecham Group p.l.c.) describes 5-ΗΤβ receptor antagonists derived from a benzoic acid nucleus 2,3 disubstituted by alkylenedioxy.
It has now been discovered that certain of the compounds embraced by the 5 general formulae disclosed therein, and related compounds, have 5-HT4 receptor antagonist properties, and are therefore of potential use in the treatment of IBS or atrial arrhythmias and stroke.
The compounds of the present invention also have a potential use in the 10 treatment of CNS disorders such as anxiety and/or migraine, in the ( treatment of upper gut motility disorders and as antiemetics.
Γ
When used herein, 'treatment' includes prophylaxis as appropriate.
Accordingly, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:
(I)
C 20 in which Χχ-(ΟΗ2)χ-Χ2 forms a 5-7 membered ring wherein:
Χχ is 0 or S;
X2 is 0, S, NR or NRCO wherein R is hydrogen or Οχ.θ alkyl;
x is 1, 2 or 3;
Rl is hydrogen, amino, halo, Οχ.β alkyl, hydroxy or Οχ.θ alkoxy; R2 is hydrogen, halo, Οχ.θ alkyl, Οχ.θ alkoxy, nitro, amino or Οχ.θ alkylthio;
R3 is hydrogen, halo, Οχ.θ alkyl, ϋχ.θ alkoxy or amino;
R4 and R5 are independently hydrogen or Οχ.θ alkyl;
YisOorNH;
Z is of sub-formula (a), (b) or (c):
P30178 (a)
(Ο wherein
-(CH2)nl is attached at carbon or nitrogen and n^ is 1, 2, 3 or 4; is 1 or 2; ηθ is 2, 3, 4 or 5; q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2;
Ra is hydrogen or a lipophilic group, such as C1.12 alkyl or aralkyl;
Rg, R7 and Rg are independently hydrogen or Ci.g alkyl; and Rg is hydrogen or C^iq alkyl;
or a compound of formula (I) wherein the CO-Y linkage is replaced by a heterocyclic bioisostere;
in the manufacture of a medicament for use as a 5-HT4 receptor antagonist.
Examples of alkyl or alkyl containing groups include Οχ, C2, C3, C4, C5, Cg, C7, Οβ, Cg, Cio> Cn or C12 branched, straight chained or cyclic alkyl, as appropriate. C1.4 alkyl groups include methyl, ethyl n- and iso-propyl, η-, iso·, sec- and terf-butyl. Cyclic alkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
Aryl includes phenyl and naphthyl optionally substituted by one or more substituents selected from halo, C^.g alkyl and Ci.g alkoxy, a suitable value for Rg aralkyl, being benzyl.
Halo includes fluoro, chloro, bromo and iodo, preferably chloro.
P30178
-4A suitable bioisostere for the amide or ester linkage containing Y in formula (I), is of formula (d) /H~5 (d) wherein the dotted circle represents one or two double bonds in any position in the
5-membered ring; H, J and I independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of H, J and I is other than carbon; U represents nitrogen or carbon.
Suitable examples of (d) are as described for X, Y and Z in EP-A-328200 (Merck Sharp & Dohme Ltd.), such as an oxadiazole moiety.
Suitable examples of the Xi-(CH2)x-X2 moiety include O-(CH2)2-O, O-(CH2)3-O, O-CH2-O, O-(CH2)2-NR4, O-(CH2)2-S or O-CH2-CONR4, wherein any of the methylene linkages are optionally mono- or disubstituted by Ci-6 alkyl groups, such as methyl. Preferably Xl-(CH2)2-X2 is O-(CH2)2*O.
Rl is preferably hydrogen or amino.
R2 is preferably hydrogen or halo.
R3 is preferably hydrogen or halo.
R4 and R5 are often hydrogen. When R4/Rs is Ομθ alkyl, it is often methyl. In particular R4 and R5 are methyl such that the disubstituent containing Χχ and X2 is O-C(CH3)2-O.
Y is preferably O.
When Z is of sub-formula (a), n1 is preferably 2, 3 or 4 when the azacycle is attached at the nitrogen atom and n^ is preferably 1 when the azacycle is attached at a carbon atom, such as the 4-position when q is 2.
P30178
-5When Z is of sub-formula (b), is preferably such that the number of carbon atoms between the ester or amide linkage is from 2 to 4 carbon atoms.
Suitable values forp andminclude p = m = l;p = 0, m = l,p = l,m = 2.
When Z is of sub-formula (c), n^ is preferably 2, 3 or 4.
Rg and Rg are preferably both alkyl, especially one of Rg and Rg is C4 or 10 larger alkyl.
c
Specific values of Z of particular interest are as follows:
(vi)
P30178
-6The invention also provides novel compounds of and within formula (I), in particular, with side chains (i), (ii), (iii), (iv), (v) or (vi).
Other values of Z of interest are described with reference to the Examples, in particular, wherein the side chain of formula (i) or (ii) is replaced by a corresponding side chain with an alkyl or optionally substituted benzyl Nsubstituent and/or wherein the 4-piperidinyl group is replaced by 3pyrrolidinyl or 3-azetidinyl.
The invention also provides novel compounds within formula (I) having Xl-(CH2)x-X2 as O-(CH2)2'O. hi particular those wherein the side chain Z is of sub-formula (a) or (c).
The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, α-keto glutaric, a-glycerophosphoric, and glucose-1-phosphoric acids.
Examples of pharmaceutically acceptable salts include quaternary .-- derivatives of the compounds of formula (I) such as the compounds quatemised by compounds Κχ-Τ wherein Κχ is Οχ.θ alkyl, phenyl-Cj.g ( 25 alkyl or C5.7 cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of Κχ include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl. Suitable examples of T include halide such as chloride, bromide and iodide.
Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
The compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.
P30178 (
-7It will also be realised that the (CH2)n2 moiety in compounds of formula (I) wherein Z is (b), may adopt an a or β or configuration with respect to the fused azabicyclic moiety.
The compounds of formula (I) wherein CO-Y is an ester or amide linkage are prepared by conventional coupling of the Z moiety with the appropriate acid. Suitable methods are as described in GB 2125398A (Sandoz Limited), GB 1593146A, EP-A-36269, EP-A-289170 and WO 92/05174 (Beecham Group p.l.c.). When CO-Y is replaced by a heterocyclic bioisostere, suitable methods are described in EP-A-328200 ( (Merck Sharp & Dohme Limited).
The invention also comprises a process for preparing the novel compounds of formula (I) which comprises reacting an appropriate benzoic add derivative with an appropriate alcohol or amine. A process comprises reacting a benzoic add derivative wherein the aromatic substituents are as required in the end compound of formula (I), or substituents convertible thereto, with an alcohol or amine containing Z or a group convertible thereto, and thereafter if necessary, converting the benzoic add substituents and/or Z, and optionally forming a pharmaceutically acceptable salt.
ζ- Suitable examples of conversions in the aromatic substituents include chlorination of hydrogen to chloro, reduction of nitro to amino, ( 25 dehydrohalogenation such as debromination, and/or elaboration of a 2,3disubstituted benzoic add with ethylene glycol to form the benzodioxan.
Suitable examples of conversions in the Z containing moiety include conventional modifications of the N-substituent by substitution and/or deprotection or, in the case of a 2-, 3- or 4- substituted piperidyl desired end compound, reduction of an appropriate pyridyl derivative.
Any elaboration of X and/or Z is, however, usually carried out prior to ester or amide coupling.
Azabicyclic side chain (CH2)n2-OH intermediates when Z is (b) in formula (I) , are known compounds or may be prepared from the ketones of formula (II) :
P30178 (Π)
according to conventional methods.
The compounds of the present invention are 5-HT4 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and
CNS disorders.
They are of potential interest in the treatment of irritable bowel syndrome (IBS), in particular the diarrhoea aspects of IBS, i.e., these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS.
They may also be of potential use in other gastrointestinal disorders, such as those associated with upper gut motility, and as antiemetics. In ¢- particular, they are of potential use in the treatment of the nausea and gastric symptoms of gastro-oesophageal reflux disease and dyspepsia.
( Antiemetic activity is determined in known animal models of cytotoxicagent/radiation induced emesis.
Specific cardiac 5-HT4 receptor antagonists which prevent atrial fibrillation and other atrial arrhythmias associated with 5-HT, would also be expected to reduce occurrence of stroke (see A. J. Kaumann 1990, Naumyn-Schmiedeberg's Arch. Pharmacol. 342, 619-622, for appropriate animal test method).
Anxiolytic activity is likely to be effected via the hippocampus (Dumuis et al 1988, Mol Pharmacol., 34, 880-887). Activity can be demonstrated in standard animal models, the social interaction test and the X-maze test.
FV··
P30178
-9Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al., 1976, Headache 16,160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT4 receptors, and hence that administration of a 5-HT4 antagonist is of potential benefit in relieving a migraine attack.
The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Such compositions are prepared by admixture and are usually adapted for enteral such as oral, nasal or rectal, or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, nasal sprays, suppositories, injectable and infusable solutions or suspensions. Orally administrable compositions are preferred, since they are more convenient for general use.
Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, ( 25 fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating.
Suitable fillers for use include cellulose, mannitol, lactose and other 30 similar agents. Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch giycollate. Suitable lubricants include, for example, magnesium stearate.
Suitable pharmaceutically acceptable wetting agents include sodium 35 lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain
P30178
-10conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
The oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
Parenteral suspensions are prepared in substantially the same manner 35 except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is
P30178
-11included in the composition to facilitate uniform distribution of the compound of the invention.
The invention further provides a method of treatment or prophylaxis of irritable bowel syndrome, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose for a 70kg adult will normally contain 0.05 to lOOOmg for example 0.5 to 500mg, of the compound of the invention. Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
No adverse toxicological effects are indicated within the aforementioned dosage ranges.
The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastro-oesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine.
The following Examples illustrate the preparation of compounds of formula (I); the following descriptions relate to intermediates (Descriptions 1-3 and 11 are nuclei incorporating intermediates containing Xi-(CH2)x-X2» Descriptions 4-9 and 10 are side chain Z containing intermediates and Descriptions 12 onwards are piperidyl intermediates prepared from the corresponding compound wherein Z is of sub-formula (a), prepared from the corresponding pyridyl derivative.
P30178
-12Examples
Ri R2 Rs Χχ/Χ2 Y z
El nh2 Cl H O-(CH2)2-O 0 (i)
E2 nh2 H H O-(CH2)2-O 0 (i)
( E3 H Br H O-(CH2)2-O 0 (i)
c E4 H H H O-(CH2)2-O 0 (i)
E5 H Cl H O-(CH2)2-O 0 (i)
E6 nh2 Cl Cl O-(CH2)2-O 0 (i)
E7 nh2 I H O-(CH2)2-O 0 (ii)
E8 nh2 Cl H O-(CH2)2-O 0 (v) ax
C E9 nh2 Cl H O-(CH2)2-O 0 (v) eq
( E10 nh2 Cl H O-(CH2)2-O 0 (ii)
Ell H Cl H O-(CH2)2-O 0 (vi) eq
E12 nh2 Cl H O-(CH2)2-O 0 (vi) eq
P30178
-13Examples (continued)
Ri r2 R3 Xl«2 Y z
E13 nh2 Cl H O-(CH2)2-O NH epm
E14 nh2 Cl H O-(CH2)2-O NH (i)
E15 nh2 Cl H O-(CH2)2-O NH (ii)
E16 nh2 Cl H O-(CH2)2-O 0 pm
E17 H H H O-(CH2)2-O ox PP
E18 H H H o-ch2-o 0 (i)
E19 H Cl H o-ch2conh 0 (i)
E20 H Cl H o-ch2conch3 0 (i)
E21 H Cl H O-(CH2)2NH 0 (i)
epm = l-ethyl-4-piperidyl 10 pm = 4-piperidylmethyl ox = where CO-Y replaced by 1,2,4-oxadiazole pp = 3-(piperidino)propyl
P30178
-14Examples (continued)
Xl/X2 = O-(CH2)2-O; Y=0
R1 r2 R3 Z
E22 nh2 Cl H l-methyl-4-piperidylmethyl
E23 nh2 Cl H l-ethyl-4-piperidylmethyl
E24 nh2 Cl H l-propyl-4-piperidylmethyl
E25 nh2 Cl H l-1butyl-4-piperidylmethyl
E26 nh2 Cl H l-cyclopropylmethyl-4-piperidylmethyl
E27 nh2 Cl H l-pentyl-4-piperidylmethyl
E28 nh2 Cl H 2-methylbutyl-4-piperidylmethyl
E29 nh2 Cl H 2-methoxyethyl-4-piperidylmethyl
E30 nh2 Cl H l-benzyl-4-piperidylmethyl
E31 nh2 Cl H 2-cyclohexylethyl-4-piperidylmethyl
E32 nh2 Cl H l-hexyl-4-piperidylmethyl
E33 nh2 Cl H l-heptyl-4-piperidylmethyl
E34 nh2 Cl H l-octyl-4-piperidylmethyl
E35 nh2 Cl H l-nonyl-4-piperidylmethyl
P30178
-15Examples (continued) [X1/X2 = O-(CH2)2-O;Y=O]
Ri r2 *3 z
E36 nh2 Cl H l-decyl-4-piperidylmethyl
E37 nh2 Cl H l-undecyl-4-piperidylmethyl
E38 nh2 Cl H l-dodecyl-4-piperidylmethyl
E39 nh2 Cl H l-(4-fluorobenzyl)-4-piperidylmethyl
E40 nh2 Cl H l-(4-methoxybenzyl)-4-piperidylmethyl
E41 nh2 Cl H l-(4-methylbenzyl)-4-piperidylmethyl
E42 nh2 Cl H l-phenylethyl-4-piperidylmethyl
[Χχ/Χ2 = O-(CH2)2-O; Y=NH]
E43 nh2 Cl H l-pentyl-4-piperidylmethyl
E44 nh2 Cl H l-cyclohexylethyl-4-piperidylmethyl
E45 nh2 Cl H l-isobutyl-4-piperidylmethyl
E46 nh2 Cl H l-(2-methylbutyl)-4-piperidylmethyl
E47 nh2 Cl H 4-piperidylmethyl
E48 nh2 Cl H l-methyl-4-piperidylmethyl
E49 nh2 Cl H l-propyl-4-piperidylmethyl
E50 nh2 Cl H l-benzyl-4-piperidylmethyl
P30178
-16Examples (continued) [X]/X2 = O-(CH2)2-O; Y=O]
Rl R2 R3 Z
E51 nh2 Cl H l-butyl-l-methyl-4-piperidylmethyl iodide
E52 nh2 I H l-butyl-4-piperidylniethyl
E53 Cl H H l-butyl-4-piperidylmethyl
E54 H Br Br l-butyl-4-piperidylmethyl
(.
(
P30178
-17Example 1
8-Amino-7-chloro-(l-butyl-4-piperidyl)methyl-l,4-benzodioxan-5carboxylate (El)
A suspension of 8-amino-7-chloro-l,4-benzodioxan-5-carboxylic acid (prepared from the corresponding 7-H acid* by chlorination of the protected form) (720 mg) was dissolved in acetonitrile (10 ml). Bis carbonyldiimidazole (500 mg) was added and the reaction mixture stirred for 2 hours. The solvent was removed in vacuo and the residue dried. A solution of l-butyl-4-piperidinemethanol (510 mg) in dry THF (20 ml) was < · added dropwise to a solution of nbutyllithium (1.88 ml of a 1.6M solution in hexane) at 0°C and the solution was stirred for 15 minutes. The imidazolide from above was redissolved in dry THF (25 ml) and the solution added dropwise to the solution of the lithium alkoxide in dry THF. The reaction mixture was stirred at room temperature overnight.
After removal of solvent the residue was partitioned between EtOAc and H2O and the EtOAc layer separated. This solution was washed several times with water and dried (MgSO4). Evaporation of solvent gave a yellow gum that was purified by column chromatography on S1O2 using CHCI3, 95%, MeOH, 5% as eluant. The product was isolated as the hydrochloride salt, mp 243-4°C.
lH NMR 250MHz (CDCI3) (free base) δ: 7.49 (s,lH), 4.48 (bs,2H), 4.26-4.38 (m,4H), 4.08 (d,2H), 2.93-3.05 (bd,2H), 2.30-2.40 (m,2H), 1.20-2.05 (m,HH), 0.90 (t,3H).
Examples 2 to 12
The following compounds were prepared analogously:
8-Amino-(l-butyl-4-piperidyl)methyl-l,4-benzodioxan-5carboxylate (E2) lH NMR 250MHz (CDCI3) (free base)
P30178
-18δ: 7.39(d,lH) 6.24(d,lH) 4.3-4.42(m,4H) 4.05-4.16(4H) 2.9-3. l(bd,2H)2.32.4(m, 2H) 1.2-2.05(m, 11H) 0.90(t,3H)
7-Bromo-5-(l-butyl-4-piperidyl)methyl-l,4-benzodioxan-5carboxylate (E3) mp 205-6°C (hydrochloride salt)
Ή NMR 250MHz (CDC13) (free base) δ: 7.5(d,lH)7.12(d,lH), 4.3-4.42(m,4H) 4.12(d,2H) 2.9-3.05(bd,2H) 2.32.4(m, 2H) 1.22-2.05(m,llH) 0.92(t,3H) (l-Butyl-4-piperidyl)methyl-l,4-benzodioxan-5-carboxylate (E4) mp 144-6°C (hydrochloride salt) iH NMR 250MHz (CDCl3)(free base) δ: 7.38(dd,lH) 7.0(dd,lH) 6.82(t,lH) 4.28-4.4(m,4H) 4.12(d,2H) 2.93.05(bd,2H) 2.3-2.4(m,2H) 1.22-2.05(m,llH) 0.92(t,3H)
7- Chloro-(l-butyl-4-piperidyl)methyl-l,4-benzodioxan-5carboxylate (E5) mp 185-6°C (hydrochloride salt) *H NMR 250 MHz (CDC13) (free base) δ: 7.37(d,lH), 7.02(d,lH),4.25-4.40(m,4H), 4.14(d,2H), 2.98(bd,2H), 2.282.38(m,2H), 1.24-2.00(m,llH), 0.92(t,3H)
8- Amino-6,7-dichloro-(l-butyl-4-piperidyl)methyl-l,4-benzodioxan
5-carboxylate (E6) mp 168-9°C (hydrochloride salt)
P30178
-19lH NMR 250 MHz (CDCI3) (free base) δ: 4.39(s,2H), 4.28-4.37(m,4H), 4.15(d,2H), 2.9-3.05(bd,2H), 2.3-2.4(m,2H), 1.22-1.98(m,llH),0.92(t,3H)
8-Amino-7-iodo-(l-cyclobexylmethyl-4-piperidyl)methyl-l,4benzodioxan-5-carboxylate (E7)
1h NMR 250 MHz (CDCI3) (free base) ' 6: 7.79(s,lH), 4.50-4.59(d,2H), 4.28-4.37(m,4H), 4.15(d,2H), 2.90-3.06 (bd,2H), 0.80-2.30(m,20H)
C
8-Amino-7-chloro-l,4-benzodioxan-(ax-3-quinolizidinyl)methyl 15 carboxylate (E8) mp 139-40°C lH NMR 250 MHz (CDCI3) (free base) δ: 7.42 (s,lH), 4.19-4.5 (m,8H) 2.72(dd,lH), 2.60(bd,lH), 1.10-2.11(m,14H)
- 8-Amino-7-chloro-l,4-benzodioxan-(e<7-3-quinolizidinyl)methyl carboxylate (E9) r 25
Th NMR 250MHz (CDCI3) (free base) δ: 7.49(s,lH), 4.48(bs,2H), 4.28-4.38(m,4H),3.95-4.15(m,2H), 3.0(bd,lH), 2.83(bd,lH), 1.01-2.20(m,14H)
8-Amino-7-chloro-(l-cyclohexylmethyl-4-piperidyl)methyl-l,4benzodioxan-5-carboxylate (E10) mp 185-6°C (hydrochloride salt) iH NMR 250MHz (CDCI3) (free base)
P30178
Ο ί 25
-20δ: 7.49(s,lH), 4.48(bs,2H), 4.30-4.38(m,4H),4.08(d,2H), 2.82-2.91(bd,2H),
2.10(d,2H), 0.80-1.95(m,18H) eg-Quinolizidin-2-ylmethyl-7-chloro-l,4-benzodioxan-5carboxy late (Ell) mp 191-192°C (hydrochloride salt) iH NMR (d6 DMSO) (HCI salt) δ: 7.24(d,lH), 7.20(d,lH), 4.28-4.36(m,4H), 4.11(d,2H), 3.25-3.36(m,2H), 2.76-3.ll(m,lH), 2.01-2.13(m,lH), 1.36-1.92(m,10H) eg-Quinolizidin-2-ylmethyl-8-amino-7-chloro-l,4-benzodioxan-5carboxylate (El2) mp 173-175°C iH NMR 250 MHz (CDC13) (free base) δ: 7.48(s,lH), 4.45(brs,2H), 4.28-4.40(m,4H), 4.07(d,2H), 2.76-2.94(m,2H), 1.00-2.15(m,14H)
Example 13
8-Amino-7-chloro-(l-ethyl-4-piperidyl)methyl-l,4-benzodioxan-5carboxamide (E13)
A solution of 8-amino-7-chloro-l,4-benzodioxan-5-carboxylic acid (see Example 1) (500mg, 0.0022mole) in acetonitrile (30ml) was treated with biscarbonyl diimidazole (356mg, 0.0022 mole). The mixture was stirred at room temperature for 2 hours.
A solution of l-ethyl-4-aminomethylpiperidine (312mg, 0.0022 mole) in acetonitrile (25 ml) was added and the reaction mixture was stirred at room temperature overnight. The solvent was removed in vacuo and the residue partitioned between EtOAc and H2O. The EtOAc layer was
P30178
-21removed, washed several times with H2O, dried (MgSO^ and concentrated to give an orange gum that was purified by column chromatography on SiO2 using chloroform with increasing proportions of methanol as eluant. The product was isolated as a pale gum.
iH NMR 250MHz (CDCI3) (free base) δ: 7.69(s,lH), 7.50(bt,lH), 4.29-4.39(m, 6H), 3.25(t,2H), 2.94(bd,2H), 2.38(dd,2H) 1.20-1.95(m,7H), 1.01(t,3H)
Examples 14 and 15
The following compounds were prepared by the method described for 15 Example 13.
8-Amino-7-chloro-(l-butyl-4-piperidyl)methyl-l,4-benzodioxan-5carboxamide (E14) mp 75-6°C iH NMR 250MHz (CDCI3) (free base) f δ: 7.73(s,lH), 7.58(bt,lH), 4.30-4.45(m,6H), 3.30(t,2H), 3.0-3.l(bd,2H), (- 25 2.39-2.48(m,2H), 2.0-2.14(bt, 2H), 1.20-1.82(m,9H), 0.92(t,3H)
8-Amino-7 -chloro- (1 -cyclohexylmethyl-4-piperi dyl)me thyl-1,4benzodioxan-5-carboxamide (E15) *H NMR 250MHz (CDCI3) (free base) δ: 7.72(s,lH), 7.55(bt,lH), 4.30-4.41(m,6H), 3.3(t,2H), 2.82-2.95(bd,2H), 2.10(d,2H), 0.78-1.9(m,18H)
P30178
-22Example 16
8-Amino-7-chloro-(4-piperidylmethyl)-l,4-benzodioxan-5carboxylate hydrochloride (E16)
a) To a stirred solution of 8-amino-7-chloro-l,4-benzodioxan-5carboxylic acid1 (1.10g) in acetonitrile was added bis-carbonyldiimidazole (0.77g). The reaction mixture was stirred at room temperature for 1.5 hours. The solvent was removed under reduced pressure to afford crude
8-amino-7-chloro-l,4-benzodioxan-5-imidazolide.
b) To a solution of N-Zert-butoxycarbonyl-4-hydroxymethyl piperidine (0.25g) in dry THF (10ml) was added methyllithium (1.5M in diethylether 0.78ml) at 0°C under a nitrogen atmosphere. Stirring was continued at ambient temperature for 10 min. 8-Amino-7-chloro-l,4-benzodioxan-5imidazolide (0.33g) in THF (10ml) was added to the reaction mixture and stirring continued for 2 hours. The reaction mixture was cooled to 0°C and water was added. The solvent was removed under reduced pressure and the residue partitioned between chloroform and water. The organic phase was washed with water (3x), dried (Na2SO4) filtered and concentrated in vacuo. Flash chromatography on silica using chloroform and ethanol as eluant gave the title compound (0.26g).
iH NMR 250MHz (CDCI3) δ: 7.47(s,lH), 4.49(s,2H), 4.08-4.22(m,4H), 2.64-2.80(m,2H), 1.842.01(m,lH), 1.70-1.83(m,2H), 1.46(s,9H), 1.18-1.38(m,2H)
c) HCKg) was bubbled into a cooled solution of 8-amino-7-chloro-(N30 tert-butoxycarbonyl-4-piperidylmethyl)-l,4-benzodioxan-5-carboxylate (0.26g) in dioxan (50ml) for 25 min. The solvent was concentrated in vacuo and the residue triturated with Et20 to afford pure title compound (0.12g).
mp 249-251°C !h NMR 250MHz (DMSO)
P30178
-23δ: 8.99-9.10(m,lH), 8.59-8.78(m,lH), 7.29(s,lH), 5.73(s,2H), 4.254.34(s,4H), 4.03(d,2H), 3.20-3.42(m,2H), 2.75-2.97(m,2H), 1.762.06(m,3H), 1.48-1.57(m,2H)
Example 17
5[3-(Piperidino)propyl]-3-[benzo-l, 4, dioxan-5-yl]-l,2,4-oxa diazole (E17) l,4-Benzodioxan-5-carboxamide oxime (D3) (0.300g 1.55 mmol) was dissolved in dry THF (10ml) with stirring, and treated with ground 4A molecular sieves (lg), under nitrogen. After 30 minutes, sodium hydride (80% dispersion in mineral oil) (0.05 lg, 1.71 mmol) was added. The mixture was then heated to reflux. After 30 minutes, the mixture was allowed to cool for a short period and ethyl-4-(piperidino) butyrate (0.340g,
1.71 mmol) was added. The reaction mixture was then heated to reflux for a further 2.5h, before being allowed to cool. The reaction mixture was then filtered. The filter pad was then washed with THF (2x). The filtrate was evaporated under reduced pressure. The residue was purified by silica-gel chromatography, eluting with pentane: EtOAc l:l->2:3 to give the title compound as a pale yellow oil, which was converted to the hydrochloride salt mp 175-176°C.
χΗ NMR 250MHz (CDC13)
5: 12.20-12.5(s br, IH), 7.52(dd, 1H)„ 6.90-7.08 (m,2H), 4.45(m,2H), 4.35(m,2H), 3.5-3.7(m,2H), 2.97-3.20(m,4H), 2.47-2.80(m,4H), 2.152.45(m,2H), 1.74-2.00(m,3H), 1.30-1.54(m, IH)
P30178
C ( 25
-24Example 18 (l-Butyl-4-piperidyl)methyl-l,3-benzodioxole-4-carboxylate hydrochloride (E18)
Following the procedure outlined in Example 1 l,3-benzodioxole-4carboxylic acid (Dll) (705 mg) was converted to the title compound (393 mg, 29%) mp 168-9°C.
lH NMR 250 MHz (CDC13) δ: 7.4 (d, IH), 6.98 (d, IH), 6.86 (t, IH), 6.10 (s, 2H), 4.20 (d, 2H), 3.04 (br d, 2H), 2.45-2.3 (m, 2H), 2.1-1.2 (m, 11H), 0.94 (t, 3H).
Examples 19 to 21
The parent acids for Examples 19-21 are described in EP-A-407137 and 313393 (Yoshitomi).
(l-Butyl-4-piperidyl)methyl-6-chloro-3,4-dihydro-3-oxo-2H-l,4benzoxazine-8-carboxylate (E19) mp 245-247°C (HCl salt) lH NMR 250 MHz, (CD3SOCD3) (HCl salt) δ: 11.17 (s, IH), 10.34-10.10 (s, IH), 7.41 (d, IH), 7.21 (d, IH), 4.80 (s, 2H),
4.22 (d, 2H), 3.57 (m, 2H), 3.20-2.85 (m, 4H), 2.12-1.95 (m, 3H), 1.90-1.60 (m, 4H), 1.40 (m, 2H), 1.00 (t, 3H) (l-Butyl-4-piperidyl)methyl-6-chloro-4-methyl-3,4-dihydro-3-oxo2H-l,4-benzoxazine-8-carboxylate (E20) mp 87-88°C iH NMR 250 MHz, (CDCI3)
P30178
-25δ: 7.49 (d, IH), 7.10 (d, IH), 4.18 (d, 2H), 3.38 (s, 3H), 3.00 (d, 2H), 2.33 (t,
2H), 1.97 (t, 2H), 1.78 (m, 3H), 1.54-1.25 (m, 6H), 0.92 (t, 3H) (l-Butyl-4-piperidyl)methyl-6-chloro-3,4-dihydro-2H-l,4benzoxazine-8-carboxylate (E21) mp 177-178°C (HCl salt) !H NMR 250 MHz, (CD3SOCD3) (HCl salt) δ: 10.28 (s, IH), 6.85 (m, 2H), 6.58 (s, IH), 4.23 (t, 2H), 4.15 (d, IH), 3.67 (d, 2H), 3.45 (m, 3H), 3.10-2.90 (m, 3H), 2.15-1.92 (m, 3H), 1.88-1.60 (m, 4H), 1.40 (m, 2H), 1.00 (t, 3H)
Example 22
8-Amino-7-chloro-5-(l-methyl-4-piperidinylmethyl)-l,420 benzodioxan carboxyiate hydrochloride (E22)
To a solution of 8-amino-7-chloro-5-(lH-4-piperidylmethyl)-l,4f benzodioxan carboxyiate (E15) (lOOmg) and triethylamine (70μ1) in acetone (15ml) was added iodomethane (20μ1). The reaction mixture was 25 stirred at ambient temperature for 64h. The solvent was concentrated under reduced pressure and the residue partitioned between chloroform and water. The organic phase was dried (Na2SO4), filtered and concentrated in vacuo. Chromatography on silica using chloroform and ethanol as the eluant gave pure product. Treatment with ethereal HCl afforded the title compound (40mg).
iH NMR 250 MHz (CDCI3) (free base) δ: 7.49 (s, IH), 4.53 (bs, 2H), 4.31-4.44 (m, 4H), 4.19 (d, 2H), 3.49 (d, 2H), 35 2.69-2.85 (m, 5H), 1.97-2.15 (m, 5H)
P30178
-26Examples 23 to 43
Following the procedure outlined in Example 22, from the compound of Example 16, the following compounds were obtained:
8-Amino-7-chloro-5-(l-ethyl-4-piperidyl)methyl-l,4-benzodioxan carboxylate hydrochloride (E23) lH NMR 250MHz (CDC13) (free base) 10 f δ: 7.47 (s, IH), 4.53 (bs, 2H), 4.29-4.46 (m, 4H), 4.17 (d, 2H), 3.44 (d, 2H),
2.95 (q, 2H), 2.51-2.69 (m, 2H), 1.90-2.12 (m, 5H), 1.40 (t, 3H)
8-Amino-7-chloro-5(l-propyl-4-piperidyl)methyl-l,4-benzodioxan carboxylate hydrochloride (E24) iH NMR 250 MHz (CD3OD) δ: 7.44 (s, IH), 4.27-4.38 (m, 4H), 4.16 (d, 2H), 3.64 (d, 2H), 2.94-3.13 (m,
4H), 2.03-2.17 (m, 3H), 1.59-1.88 (m, 4H), 1.03 (t, 3H)
8-Amino-7-chloro-5-(l-isobutyl-4-piperidyl)methyl-l,4-benzodioxan (- carboxylate hydrochloride (E25)
NMR 250MHz (CDCI3) (free base) δ: 7.50 (s, IH), 4.48 (bs, 2H), 4.31-4.39 (m, 4H), 4.09 (d, 2H), 2.89 (d, 2H), 2.08 (d, 2H), 1.69-1.95 (m, 6H), 1.31-1.49 (m, 2H), 0.91 (d, 6H)
8-Ammo-7-chloro-5-(l-cyclopropylmethyl-4-piperidyl)methyl-l,4benzodioxan carboxylate hydrochloride (E26) iH NMR 250MHz (CDCI3) (free base) δ: 7.49 (s, IH), 4.52 (bs, 2H), 4.29-4.45 (m, 4H), 4.14 (d, 2H), 3.39 (d, 2H), 2.58 (d, 2H), 2.29-2.48 (m, 2H), 1.69-2.00 (m, 5H), 1.04-1.18 (m, IH), 0.54 (d, 2H), 0.27 (d, 2H)
P30178
-278-Amino-7-chloro-5-(l-pentyl-4-piperidinyl) methyl- 1,4-benzodioxan carboxylate hydrochloride (E27) lH NMR 250MHz (CD3OD) δ: 7.43 (s, IH), 4.31-4.41 (m, 4H), 4.17 (d, 2H), 3.65 (d, 2H), 2.95-3.17 (m, 4H), 2.01-2.18 (m, 3H), 1.61-1.86 (m, 4H), 1.29-1.49 (m, 4H), 0.95 (t, 3H)
8-Amino-7-chloro-5-(2-methylbutyl-4-piperidyl)methyl-l,410 benzodioxan carboxylate hydrochloride (E28) {’
I lH NMR 250MHz (CD3OD) δ: 7.43 (s, IH), 4.28-4.43 (m, 4H), 4.18 (d, 2H), 3.65 (d, 2H), 2.95-3.19 (m,
4H), 2.02-2.19 (m, 3H), 1.59-1.78 (m, 5H), 0.97 (d, 6H)
8-Amino-7-chloro-5-(2-methoxyethyl-4-piperidyl)methyl-l,4benzodioxan carboxylate hydrochloride (E29) iH NMR 250MHz (CDCI3) (free base) δ: 7.49 (s, IH), 4.49 (bs, 2Η), 4.30-4.42 (m, 4H), 4.11 (d, 2H), 3.52 (t, 2H),
3.35 (s, 3H), 3.01 (d, 2H), 2.60 (t, 2H), 2.03 (t, 2H), 1.73-1.84 (m, 3H), 1.381.57 (m, 2H)
8-Amino-7-chloro-5-(l-benzyl-4-piperidyl)methyl-l,4-benzodioxan carboxylate hydrochloride (E30) !h NMR 250MHz (CDCI3) (free base) δ: 7.49 (s, IH), 7.22-7.40 (m, 5H), 4.49 (bs, 2H), 4.28-4.52 (m, 4H), 4.10 (d, 2H), 3.50 (s, 2H), 2.94 (d, 2H), 2.00 (t, 2H), 1.70-1.85 (m, 3H), 1.33-1.51 (m, 2H)
8-Amino-7-chloro-5-(2-cyclohexylethyl-4-piperidinyl)methyl-l,4benzo dioxan carboxylate hydrochloride (E31) iH NMR 250 MHz (CDCI3) (free base)
P30178
-28δ: 7.49 (s, 1Η), 4.47 (bs, 2H), 4.29-4.41 (m, 4H), 4.10 (d, 2H), 3.01 (d, 2H), 2.33-2.44 (m, 2H), 1.99 (t, 2H), 1.35-1.87 (m, 12H), 1.10-1.31 (m, 4H), 0.83 1.01 (m, 2H)
8-Amino-7-chloro-5-(l-hexyl-4-piperidyl)methyl-l,4-benzodioxan carboxylate hydrochloride (E32) lH NMR 250 MHz (CDC13) (free base) δ: 7.47(s,lH), 4.48(bs,2H), 4.32-4.42(m,4H), 4.15(d,2H), 3.09-3.24(m,2H),
2.46-2.59(m,2H), 2.09-2.28(m,2H), 1.79-1.91(m,3H), 1.55-1.73(m,4H), 1.251.37(m,6H), 0.84-0.92(m,3H)
8-Amino-7-chloro-5-(l-heptyl-4-piperidyl)methyl 1,4-benzodioxan carboxylate hydrochloride (E33) lH NMR 250 MHz (CDCI3) (free base) δ: 7.48(s,lH), 4.46(bs,2H), 4.30-4.39(m,4H), 4.12(d,2H), 3.11(d,2H), 2.47(t,2H), 2.04(t,2H), 1.79-1.90(m,3H), 1.52-1.69(m,4H), 1.29-1.45(m,8H), 0.83-0.91(m,3H)
8-Amino-7-chloro-5-(l-octyl-4-piperidyl)methyl-l,4-benzodioxan carboxylate hydrochloride (E34) *H NMR 250 MHz (CDCI3) (free base) δ: 7.50(s,lH), 4.46(m,2H), 4.31-4.39(m,4H), 4.12(d, 2H), 3.04-3.13(m,2H), 2.38-2.48(m,2H), 2.01-2.16(m,2H), 1.77-1.88(m,3H), 1.51-1.65(m,4H), 1.241.32(m,10H), 0.85-0.91(m,3H)
8-Amino-7-chloro-5-(l-nonyl-4-piperidyl)methyl-1,4-benzodioxan carboxylate hydrochloride (E35) iH NMR 250 MHz (CDCI3) (free base)
P30178
-29δ: 7.47(s,lH), 4.51(bs,2H), 4.31-4.40(m,4H), 4.14(d,2H), 3.22(d,2H), 2.59(t,2H), 2.31(t,2H), 1.62-1.94(m,7H), 1.21-1.35(m,12H), 0.850.93(m,3H)
8-Amino-7-chloro-5-(l-decyl-4-piperidyl)methyl-l,4-benzodioxan carboxylate hydrochloride (E36) lH NMR 250 MHz (CDC13) (free base) δ: 7.41(s,lH), 4.44(bs,2H), 4.24-4.32(m,4H), 4.08(d,2H), 3.15(d,2H), 2.4810 2.57(m,2H), 2.24(d,2H), 1.57-1.88(m,7H), 1.13-1.28(m,14H), 0.790.84(m,3H)
8-Amino-7-chloro-5-(l-undecyl-4-piperidyl)metbyl 1-4-benzodioxan carboxylate hydrochloride (E37)
Ih NMR 250 MHz (CDCI3) (free base) δ: 7.49(s,lH), 4.50(bs, 2H), 4.32-4.41(m,4H), 4.15(d,2H), 3.19(d,2H), 2.502.58(m,2H), 2.17-2.29(m,2H), 1.80-1.92(m,3H), 1.60-1.78(m,4H), 1.2120 1.35(m,16H), 0.88-0.92(m,3H)
8-Amino-7-chloro-5-(l-dodecyl-4-piperidyl)methyl-l,4-benzodioxan carboxylate hydrochloride (E38) *H NMR 250 MHz (CDCI3) (free base) δ: 7.49(s,lH), 4.49(bs,2H), 4.33-4.41(m,4H)> 4.14(d,2H), 3.18(d,2H), 2.492.57(m,3H), 2.22(t,2H), 1.80-1.94(m,3H), 1.57-1.76(m,4H), 1.221.33(m,18H), 0.85-0.91(m,3H)
8-Amino-7-chloro-5-(l-(4-fluorobenzyl)-4-piperidyl)methyl-l,4benzodioxan carboxylate hydrochloride (E39) χΗ NMR 250 MHz (CDCI3) (free base) δ: 7.48(s,lH), 7.27-7.38(m,2H), 7.01(t,2H), 4.49(bs,2H), 4.30-4.39(m,4H), 4.11(d,2H), 3.53(s,2H), 2.94(d,2H), 2.04(t,2H), 1.72-1.84(m,3H), 1.391.52(m,2H)
P30178
-308-Amino-7-chloro-5-(l-(4-methoxybenzyl)-4-piperidyl)methyl-l,4benzodioxan carboxylate bydrocbloride (E40) lH NMR 250 MHz (CDC13) (free base) δ: 7.48(s,lH), 7.22(d,2H), 6.85(d,2H), 4.49(bs,2H), 4.29-4.36(m,4H), 4.09(d,2H), 3.78(s,3H), 3.47(s,2H), 2.91(d,2H), 1.96(t,2H), 1.701.80(m,3H), 1.29-1.47 (m,2H)
8-Amino-7-chloro-5-(l-(4-methylbenzyl)-4-piperidyl)methyl-l,4benzodioxan carboxylate hydrochloride (E41) lH NMR 250 MHz (CDCI3) (free base) δ: 7.48(s,lH), 7.22(d,2H), 7.12(d,2H), 4.45(bs,2H), 4.30-4.38(m,4H), 4.10(d,2H), 3.47(s,2H), 2.92(d,2H), 2.33(s,3H), 2.00(t,2H), 1.701.81(m,3H), 1.32-1.50(m,2H).
8-Amino-7-chloro-5-(l-phenethyl-4-piperidyl)methyl-l,4benzodioxan carboxylate hydrochloride (E42) *H NMR 250 MHz (CDCI3) (free base) δ: 7.50(s,lH), 7.15-7.34(m,5H), 4.49(bs,2H), 4.28-4.41(m,4H), 4.13(d,2H), 3.07(d,2H), 2.79-2.89(m,2H), 2.55-2.65(m,2H), 2.07(t,2H), 1.71-1.90(m,3H), 1.38-1.54(m,2H)
Example 43
8-Amino-7-chloro-l,4-benzodioxan-5-(l-pentyl-4-piperidyl)methyl carboxamide hydrochloride (E43)
A solution of 8-acetamido-7-chlorobenzodioxan-5-(l-pentyl-4piperidylmethyl carboxamide (D13) (60mg) in ethanol (10ml) was treated with 10% aqueous NaOH solution (110μ1). The resultant mixture was heated to reflux for 5h. The solvent was removed in vacuo and the residue
P30178
-31partitioned between water and chloroform. The organic phase was dried (Na2SO4) filtered and concentrated in vacuo to afford an oil. Treatment with ethereal HCl gave pure title compound (39mg).
lH NMR 250 MHz (CDC13) (free base)
5: 7.70(s,lH), 7.42-7.53(m,lH), 4.24-4.49(m,6H), 3.27(t,2H), 2.88(d,2H),
2.18- 2.28(m,2H), 1.84(t,2H), 1.13-1.71(m,llH), 0.83(t,3H)
Examples 44-46
Following the procedure outlined in Example 43 the following compounds were obtained:
8-Amino-7-chloro-l,4-benzodioxan-5-(l-cyclohexylethyl-4piperidinyl)methyl carboxamide hydrochloride (E44) iH NMR 250 MHz (CDCI3) (free base) δ: 7.69 (s,lH), 7.42-7.53(m,lH), 4.22-4.38(m,6H), 3.24(t,2H), 2.85(d,2H),
2.18- 2.31(m,2H), 1.81(t,2H), 0.95-1.72(m,16H), 0.70-0.93(m,2H)
8-Amino-7-chloro-l,4-benzodioxan-5-(l-isobutyl-4-piperidyl)methyl 25 carboxamide hydrochloride (E45) lH NMR 250 MHz (CDCI3) (free base) δ: 7.78(s,lH), 7.49-7.59(m,lH), 4.32-4.45(m,6H), 3.34(t,2H), 2.88(d,2H),
2.07(d,2H), 1.52-1.91(m,6H), 1.23-1.40(m,2H), 0.89(d,6H).
8-Amino-7-chloro-l,4-benzodioxan-5-(l-(2-methylbutyl)-4piperidyl)methyl carboxamide hydrochloride (E46) χΗ NMR 250 MHz (CDCI3) (free base)
P30178
-32δ: 7.70(8,IH), 7.44-7.53(m,lH), 4.24-4.37(6H), 3.28(t,2H), 2.87(d,2H), 2.192.29(m,2H), 1.75-1.90(m,2H), 1.42-1.71(m,4H), 1.15-1.37(m,4H), 0.83(d,6H).
Example 47
8-Amino-7-chloro-l,4-benzodioxan-5-(4-piperidyl)methyl carboxamide hydrochloride (E47)
A solution of 8-acetamido-7-chloro-l,4-benzodioxan-5-(4-piperidyl)methyl carboxamide (D12) (1.65g) in ethanol (50ml) was treated with 10% aqueous sodium hydroxide solution (4.5ml) and the resulting mixture heated to reflux overnight. The solvent was removed in vacuo, the residue saturated with K2CO3 and extracted with chloroform. The organic phase was dried (Na2SC>4) filtered and evaporated under reduced pressure to afford 8-amino-7-chloro-l,4-benzodioxan-5-(4piperidyDmethylcarboxamide (0.89g). Treatment with ethereal HCl gave the title compound.
iH NMR 250 MHz (CDCI3) (free base) δ: 7.74(s,lH), 6.48-7.54(m,lH),'4.26-4.48(m,6H), 3.32(t,2H), 3.09(d,2H), 2.59(dt,2H), 2.03(bs,lH), 1.62-1.81(m,3H), 1.08-1.28(m,2H)
Examples 48*50
Following the procedure outlined in Description 13 the following compounds were prepared.
8-Amino-7-chloro-l,4-benzodioxan-5-(l-methyl-4-piperidyl)methyl carboxamide hydrochloride (E48) lH NMR 250 MHz (CD3OD) free base δ: 8.15-8.25(m,lH), 7.45(s,lH), 4.31-4.48(m,4H), 3.51(d,2H), 3.373.41(m,2H), 3.0(t,2H), 2.84(s,3H), 1.88-2.09(m,3H), 1.42-1.63(m,2H)
P30178
-338-Amino-7-chloro-l,4-benzodioxan-5-(l-npropyl-4-piperidyl)methyl carboxamide hydrochloride (E49) !H NMR 250 MHz (CD3OD) (free base) δ: 7.53(s,lH), 4.38-4.54(m,4H), 3.57(d,2H), 3.27-3.41(m,2H), 2.833.15(m,4H), 1.54-2.12(m,7H), 1.03(t,3H)
8-Amino-7-chloro-l,4-benzodioxan-5-(l-benzyl-4-piperidyl)methyl carboxamide hydrochloride (E50) lH NMR 250 MHz (CDCI3) δ: 7.75(s,lH), 7.48-7.60(m,lH), 7.17-7.38(m,5H), 4.28-4.46(m,6H), 3.49(s,2H), 3.31(t,2H), 2.91(d,2H), 1.98(t,2H), 1.52-1.78(m,3H), 1.231.42(m,2H).
M+ (El) 359
Example 51
8-Amino-7-chloro-(l-butyl-l-methyl-4-piperidyl)methyl-l,4benzodioxan-5-carboxylate iodide (E51)
A solution of 8-amino-7-chloro-(l-butyl-4-piperidyl)methyl-l,4benzodioxan-5-carboxylate hydrochloride (El) (75mg) was converted to the free base then dissolved in acetone (10ml). Iodomethane (20μπι1) was added and the mixture was heated under reflux for 3 hours. The solvent was removed in vacuo and the residue dried to give a pale yellow solid (70 mg). The product exists in two isomeric forms.
*H NMR 250 MHz (DMSO) δ: 7.28(s,lH), 5.72(bs,2H), 4.28(bs,4H), 4.08(d,2H), 3.38-3.5(m,2H), 3.23.37(m,4H), 3.00(s,3H), 1.20-2.05(m,9H), 0.92(t,3H).
P30178
-34Example 52
8-Amino-7-iodo-l,4-benzodioxan-5-(l-butyl-4-piperidyl)methyl carboxylate hydrochloride (E52)
The title compound was prepared from 8-amino-7-iodo-l,4-benzodioxan-5 carboxylic acid (DI) by the method described for Example 1.
lH NMR 250 MHz (CDC13) 10 δ: 7.81(s,IH), 4.53(bs,2H), 4.29-4.40(m,4H), 4.09(d,2H), 2.91-3.08(m,2H), 2.28-2.44(m,2H), 1.89-2.08(m,2H), 1.69-1.88(m,3H), 1.23-1.60(6H), 0.93(t,3H).
Example 53 (l-Butyl-4-piperidyl)methyl-8-chloro-l,4-benzodioxan-5carboxylate (E53)
The title compound was prepared from 8-chloro-l,4-benzodioxan-5carboxylic acid 1 by the method described for Example 1.
( mp 153-154°C (hydrochloride salt) ( 25 lH NMR 250 MHz (CDCI3) (free base) δ: 7.38(d,lH), 6.96(d,lH), 4.41(s,4H), 4.13(d,2H), 2.98(d,2H), 2.32(t,2H), 1.93(t,2H), 1.84-1.65(m,3H), 1.54-1.20(m,6H), 0.92(t,3H)
Example 54 (l-Butyl-4-piperidyl)methyl-6,7-dibromo-l,4-benzodioxan-535 carboxylate (E54)
The title compound was prepared from 6,7-dibromo-l,4-benzodioxan-5carboxylic acid 1 by the method described for Example 1.
P30178
-35mp 175-177°C (hydrochloride salt) lH NMR 250MHz (CDC13) (free base) δ: 7.20(s,lH), 4.30(s,4H), 4.20(d,2H), 3.02(d,2H), 2.38(t,2H), 2.00(t,2H), 1.87-1.65(m,3H), 1.55-1.28(m,6H), 0.94(t,3H)
Descriptions (preparation of intermediates)
Description 1 (intermediate for Example 7)
8-Amino-7-iodo-l,4-benzodioxan-5-carboxylic acid
A solution of 8-amino-l,4-benzodioxan-5-carboxylic acid^(500mg, 0.0025m) in AcOH(50ml) was treated with a solution of iodine monochloride (0.423g, 0.0026) in AcOH(lOml). The reaction mixture was stirred at room temperature for two days. The solvent was removed in vacuo and the residue treated with H2O. A red solid was obtained which was collected by filtration and washed with water. Yield=0.60g.
lH NMR (250MHz) DMSO δ: 7.69(s,lH), 5-5.5(b,lH), 4.3(s,6H)
Description 2 (intermediate for Example 6)
8-Amino-6,7-dichloro-1.4-benzodioxan-5-carboxylic acid
8-Acetamido-l,4-benzodioxan-5-carboxylic acid^ (6.14g, 0.029m) was suspended in AcOH(200ml) and a solution of CI2 in AcOH (52ml of a solution of 9.6g in 100ml) was added. The reaction mixture was stirred at room temperature overnight. The solvent was removed in vacuo and the
P30178
-36residue was triturated with water. The precipitated solid was collected by filtration, washed with water and dried to give 6.20g product.
IH NMR (250MHz) DMSO δ: 12.4-12.5(b,lH), 9.3(bs,lH), 4.35(s,4H), 2.07(s,3H)
Description 3 (intermediate for Example 17)
1.4- Benzodioxan-5-carboxamide oxime
Sodium (0.720g, 0.031 mol) was dissolved with stirrring in methanol (8ml). A solution of hydroxylamine hydrochloride (2.18g, O.031 mol) in methanol (40 ml) was then added dropwise. The mixture was then stirred at room temperature for 1/2 hour. The reaction mixture was then filtered, and the filter pad washed with MeOH. The filtrate was then treated with
1.4- benzodioxan-5-nitrile2 (2.52g, 0.016 mol). The reaction mixture was then stirred and heated to reflux. After 12h, the reaction mixture was allowed to cool, and was evaporated under reduced pressure to give a brown oily solid. Recrystallisation of this residue from methanol gave the title compound as cream coloured crystals (2.57g) mp 146-148°C.
lH NMR (250MHz) DMSO δ: 9.42(s,lH), 6.75-6.96(m,3H), 5.62(s,2H), 4.25(s,4H)
Description 4 (Z is of sub-formula (i), Y=O)
-Bu tyl-4-pi peridin em e thanol
A mixture of ethyl isonipecotate (31.4g, 0.2mole), K2CO3 (54g, 0.4mole) and nBuBr (27.4g, 0.2mole) in EtOH (400ml) was stirred under reflux for
3 hours. The reaction mixture was allowed to cool, filtered through keiselguhr and the filtrate concentrated to give a pale yellow oil. This was dissolved in dry Et£O (200ml) and added dropwise to a suspension of LiAIH4 (20g, 0.26mole) in dry Et20. The reaction mixture was stirred at
P30178
-37room temperature overnight then cooled in an ice bath. Water (20ml) was carefully added, followed by 20% aq. NaOH (20ml), followed by water (60ml). The mixture was stirred at room temperature for 30 minutes then filtered through keiselguhr. The filtrate was concentrated in vacuo to give a colourless oil (25.0g).
iNMR 250MHz (CDCI3) δ: 3.48(d,2H), 2.93-2.99(bd,2H), 1.18-2.4(m,14H), 0.9(t,3H)
Description 5 (Z is of sub-formula (ii), Y=O) l-Cyclohexylmethyl-4-piperidinemethanol
This compound was prepared by the method described in Description 4 from ethyl isonipecotate and cyclohexylmethylbromide.
lH NMR 250MHz, (CDCI3) δ: 3.48(d,2H), 2.84-2.94(bd,2H), 0.78-2.4(m,21H inc. d,2H)
Description 6 (Z is of sub-formula (ii), Y=NH2)
4-Aminomethyl-l-cycIohexylmethylpiperidine
A solution of isonipecotamide (7g,0.055mole) in EtOH (150ml) was treated with K2CO3 (13.8g, O.lmole) and cyclohexylmethylbromide (12.4g,
0.07mole) and the reaction mixture was heated under reflux overnight.
The mixture was allowed to cool, the solid removed by filtration through keiselguhr and the filtrate concentrated in vacuo to give a pink solid (7.3g). This amide was suspended in dry THF (30ml) and the suspension brought to reflux. BH3.Me2S (4.8ml) was added dropwise over 15 minutes then the mixture was heated under reflux for a further hour. Me2S was removed from the mixture using a reflux ratio head. Heating was continued overnight and the reaction mixture was then cooled. 5N HCl (6ml) was added then the mixture was heated under reflux overnight.
P30178
-38The solution was cooled, basified with 40% aq. NaOH and extracted with CHCI3. Drying and evaporation of solvent gave a colourless oil.
iH NMR 250MHz (CDCI3) δ: 2.8-2.91(bd,2H), 2.55(d,2H), 2.09(d,2H), 0.75-1.9(m,20H)
Description 7 (Z is of sub-formula (i), Y=NH)
4-Aminomethyl-l-butylpiperidine
The title compound was prepared by the method described in Description 6 from isonipecotamide and butyl bromide.
iH NMR 250 MHz (CDCI3) δ: 2.88-3.0(bd,2H), 2.56(d,2H), 1.18-1.95(m,15H), 0.92(t,3H)
Description 8 (Z is epm, Y=NH)
4-Aminomethyl- 1-e thy lpiperi dine
The title compound was prepared by the method described in Description 6 from isonipecotamide and ethyl iodide.
iH NMR 250MHz (CDCI3)
8:2.9-3.0 (bd,2H), 2.56(d,2H), 2.48(dd,2H), l.l-1.95(m,9H), 1.05(t,3H)
Description 9 (Z is pm, Y=O)
N-terf-Butoxycarbonyl-4-hydroxymethylpiperidine
To a stirred slurry of L1AIH4 (14.48g) in Et£O (200ml) was added, dropwise, a solution of ethyl isonipecotate (19.3ml) in Et20 (100ml) at 0°C
P30178
-39under a nitrogen atmosphere. Stirring was continued at room temperature overnight. The mixture was cooled and H2O (14.5ml), 10% aqueous NaOH (21.8ml) and H2O (36.2ml) were added sequentially. The mixture was stirrred at room temperature for lh. The precipitate was removed by filtration through keiselguhr and the filtrate concentrated under reduced pressure to afford crude 4-hydroxymethylpiperidine (4.7 lg). Di-terf-butyl dicarbonate (9.83g) was added to a solution of 4hydroxymethylpiperidine (4.7lg) in 50% aqueous THF. Solid K2CO3 was added to the reaction mixture to maintain pH 9, and the mixture stirred overnight at room temperature. The solvent was concentrated under reduced pressure and the residue partitioned between Et20 and H2O.
The aqueous phase was extracted with Et20 and the combined organic phase dried (Na2SO4) filtered and concentrated in vacuo to afford the title compound as a pale yellow solid (6.12g).
lH NMR 250MHz (CDCI3) δ: 4.08-4.2(bd, 2H), 3.45-3.52(bt,2H), 2.6-2.78(m,2H), 1.58-1.9(m,4H), 1.46(s,9H), 1.03-1.22(m,2H)
Description 10 eq - 2-Hydroxymethylquinolizidine was prepared by the method of N.J. Leonard et al. J. Org. Chem., 1957 22, 1445 eq - 3-Hydroxymethylquinolizidine was prepared by the method of H. Lewis and C. Shoppee J. Chem. Soc., 1956, 313.
P30178
-40Description 11 (intermediate for Example 18)
a) Ethyl-l,3-benzodioxole-4-carboxylate
Following the procedure outlined by J. H. Clark et al, Tetrahedron Letters No. 38, 3361,1976, ethyl-2,3-dihydroxybenzoate (4.5g) was converted to the title compound (2.2lg, 46%).
iH NMR 250 MHz (CDC13) δ: 7.42 (d, IH), 6.98 (d, IH), 6.86 (t, IH), 6.11 (s, 2H), 4.40 (q, 2H), 1.40 (t, 3H).
b) l,3-Benzodioxole-4-carboxylic acid
A solution of ethyl-l,3-benzodioxole-4-carboxylate (D13) (lg) in water (5 ml) and ethanol (8 ml) was treated with 10% sodium hydroxide solution (3.1 mis) and heated at reflux for 30 minutes. After cooling, the reaction mixture was acidified with dilute hydrochloric acid, and the precipitate was filtered and washed with water to give the title compound (D13) (0.7lg, 84%).
iH NMR 250 MHz (d6-DMSO) δ: 13.01 (br s, IH), 7.29 (d, IH), 7.13 (d, IH), 6.90 (t, IH), 6.13 (s, 2H).
Description 12 (intermediate for Example 47)
a) 8-Acetamido-l,4-benzodioxan-5-(4-pyridyl)methyl carboxamide
8-Acetamido-l,4-benzodioxan-5-carboxylic acid (2.5g) was suspended in acetonitrile (100 ml) and Ν,Ν’-carbonyl diimidazole (1.7g) was added. The reaction mixture was stirred with gentle heating, under a nitrogen atmosphere for lh. The mixture was cooled to room temperature and the solvent concentrated in vacuo. The oil was filtered through a bed of silica using chloroform and ethanol as eluant. The oil was dissolved in
P30178
-41dichloromethane (100ml) and treated with 4-(aminomethyl)pyridine (1.17ml). The resulting mixture was heated to reflux overnight. The solution was cooled to room temperature and the solvent removed in vacuo. The residue was chromatographed on silica eluting with ethanol/chloroform to afford pure title compound as a solid (1.47g).
lH NMR 250 MHz (CDCI3) δ: 8.58(d,2H), 8.10(d,lH), 7.92-8.00(m,lH), 7.82(d,lH), 7.69(bs, IH),
7.28(d,2H), 4.68(d,2H), 4.39-4.47(m,4H), 2.24(s,3H)
b) 8-Acetamido-l,4-benzodioxan-5-(4-piperidyl)methyl carboxamide
A solution of 8-acetamido-l,4-benzodioxan-5-(4-pyridyl)methyl carboxamide (3.0g) in acetic acid (200 ml) was hydrogenated at 50 psi over platinum (iv) oxide. After 4h the catalyst was removed by filtration through keiselguhr and the filtrate concentrated in vacuo. The residue was taken up in water, basified with K2CO3 and extracted into chloroform. The organic phase was dried (Na2SC>4) filtered and concentrated in vacuo to afford the title compound (2.85g) lH NMR 250 MHz (CDCI3) δ: 8.03(d,lH), 7.70-7.80(m,2H), 7.55-7.63(m,lH), 4.35(m,4H), 3.24(t,2H), 3.10(d,2H), 2.59(t,2H), 2.12(s,3H), 2.09(bs,lH), 1.68-1.80(m,3H), 1.111.29(m,2H).
c) 8-Acetamido-7-chloro-l,4-benzodioxan-5-(4’piperidyl)methyl carboxamide
A solution of 8-acetamido-l,4-benzodioxan-5-(4piperidyDmethylcarboxamide (2.56g) in acetic acid (100 ml) was treated with a solution of chlorine (0.55g) in acetic acid (18 ml). The reaction mixture was stirred at ambient temperature overnight. The solvent was removed in vacuo to afford the title compound as a gum (D12).
lH NMR 250 MHz (CD3OD)
P30178
-42δ: 7.47(s,lH), 4.29-4.46(m,4H), 3.29-3.49(m,4H), 3.01(t,2H), 2.122.21(m,3H), 1.99(s,3H), 1.43-1.62(m,2H) ί
r (
ί 25
Description 13 (intermediate for Example 43)
8-Acetamido-7-chloro-l,4-benzodioxan-5-(l-pentyl-4piperidyl)methyl carboxamide
To a solution of 8-acetamido-7-chloro-l,4-benzodioxan-5-(4piperidylmethybcarboxamide (D12) (150mg) in acetone (15ml) was added potassium carbonate (lOOmg) and 1-bromopentane (60μ1). The resulting mixture was stirred overnight at ambient temperature. The solvent was removed in vacuo and the residue chromatographed on silica using chloroform and ethanol as eluant to afford pure product (D13) (60mg).
iH NMR 250 MHz (CDC13) δ: 7.72-7.79(s,lH), 7.55-7.65(m,lH), 7.21-7.34(m,lH), 4.32-4.50(m,4H), 3.45(t,2H), 3.03(d,2H), 2.43-2.55(t,2H), 2.15-2.29(m,3H), 2.01(t,2H), 1.211.82(m,llH), 0.91(t,3H)
Descriptions 14 to 16 (intermediates for Examples 44-46)
Using the procedure outlined in Description 13 the following compounds were prepared:
8-Acetamido-7-chloro-l,4-benzodioxan-5-(l-cyclohexylethyl-4piperidyl)methyl carboxamide (D14) iH NMR 250 MHz (CDCI3) δ: 7.70(s,lH), 7.47-7.55(m,2H), 4.30-4.47(m, 4H), 3.46(t,2H), 3.01(d,2H), 2.34-2.45(m,2H), 2.21(bs,3H), 1.99(t,2H), 1.57-1.82(m,8H), 1.091.49(m,8H), 0.83-1.00(m,2H)
P30178
-438-Acetamido-7-chloro-l,4-benzodioxan-5-(l-isobutyl-4piperidyl)methyl carboxamide (D15) lH NMR 250 MHz (CDCI3) δ: 7.73(s,IH), 7.52-7.61(m,lH), 7.22-7.32(m,lH), 4.32-4.49(m,4H), 3.34(t,2H), 2.91(d,2H), 2.18(bs, 3H), 2.10(d,2H), 1.52-1.97(m,6H), 1.251.45(m,2H), 0.89(d,6H)
8-Acetamido-7-chloro-l,4-benzodioxan-5-(l-(2-methylbutyl)-4piperidyl)methyl-l,4-benzodioxan carboxamide (D16)
Ih NMR 250 MHz (CDCI3) δ: 7.75(s,lH), 7.55-7.65(m,lH), 7.19-7.30(m,lH), 4.33-4.5l(m,4H), 3.33(t,2H), 3.02(d,2H), 2.33-2.44(m,2H), 2.19(bs,3H), 2.01(t,2H), 1.371.81(m,8H), 0.90(d,6H)
References:
1. UK Patent 1571278
2. R.C. Fuson, R. Gaertner, A.D.H. Chadwick, J.Org.Chem. 1948, 13,489
P30178
-445-HT4 RECEPTOR ANTAGONIST ACTIVITY
1) Guinea pig colon
Male guinea-pigs, weighing 250-400g are used. Longitudinal musclemyenteric plexus preparations, approximately 3cm long, are obtained from the distal colon region. These are suspended under a 0.5g load in isolated tissue baths containing Krebs solution bubbled with 5% CO2 in O2 and maintained at 37°C. In all experiments, the Krebs solution also contains methiothepin lO'^M and granisetron 10*θΜ to block effects at δ-ΗΤχ,
5-HT2 and 5-HT3 receptors.
After construction of a simple concentration-response curve with 5-HT, using 30s contact times and a 15min dosing cycle, a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 4070% maximumdO'^M approx). The tissue is then alternately dosed every 15min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP). After obtaining consistent responses to both 5-HT and DMPP, increasing concentrations of a putative
5-HT4 receptor antagonist are then added to the bathing solution. The effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, PIC5Q values are determined, being defined as the -log concentration of antagonist which reduces the contraction by 50%. A compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT4 receptor antagonist.
Compounds were generally active in the range of concentrations of the order of pIC5Q=7 or more, with the compounds of Examples 1, 2, 3, 5, 6, 9, 11,12, 21, 22, 25, 26, 27, 28, 30, 31, 32, 33, 35, 39, 40, 41, 42, 44, 49 and 53 having particularly good activity.
P30178
-452) Piglet Atria
The compounds were tested in the piglet spontaneous beating atrium screen (Naunyn-Schmiedeberg's Arch. Pharmacol 342, 619-622). pKjj (5 logio Κβ) values for the compounds of Examples 1, 2, 5,10,13,14, 52, 53 and 55 were in the range 7 to 10.
3) Rat oesophagus
Rat oesophageal tunica muscularis mucosae was set up according to Baxter et. al. Naunyn-Schmiedeberg’s Arch. Pharmacol., 343, 439-446 (1991). The inner smooth muscle tube of the muscularis mucosae was isolated and mounted for isometric tension recording in oxygenated (95%
02/5% CO2) Tyrodes solution at 37°C. All experiments were performed in pargyline pre-treated preparations (ΙΟΟμΜ for 15 min followed by washout) and in the presence of cocaine (30μΜ). Relaxant responses to 5HT were obtained after pre-contracting the oesophagus tissue with carbachol (3μΜ).
El acted as a non-surmountable antagonist of 5-HT in rat oesophagus causing as reduction in maximum response, without significant rightward displacement of concentration effect curves.
4) 5-HT-induced motility in dog gastric pouch
Compounds were tested in the in vivo method described in Stimulation of canine motility by BRL 24924, a new gastric prokinetic agent by
Bermudez et al, J. Gastrointestinal Motility, 1990, 2(4), 281-286.
Compounds showed inhibition at 10pg kg-1 and El showed inhibition at ^gkg-1.
P30178
-46IN VIVO TESTING FOR IBS
The method is as generally described in J. Physiology, 1958, Vol. 141, pl4P-15P.
Male mice (strain: CD1; weight range 25-35g) were housed individually in perspex boxes with a mesh top and bottom for 20 min prior to dosing. Animals were then challenged with either vehicle or 5-HTP (lOmg/kg) via the subcutaneous route. Antagonists were dosed (s.c.) 5 min post-dose of saline or 5-HTP. The number of pellets was counted at 10 min. intervals for 1 hr. and finally after a further 15 mins (total time = 75 min). The . animals were sacrificed. The mean and SEM of the cumulative number of pellets was calculated.
El at 10 gg/kg had no effect on faecal pellet output when compared against saline; i.e. the compound did not constipate. 5-HTP significantly potentiated the rate of pellet output, but at this dose of 10 gg/kg whilst causing wetter pellets, did not produce diarrhoea.
El dose dependently inhibited the 5-HTP effect between 0.1-lgg/kg at lgg/kg-lOOgg/kg El, the defaecation rate was returned to normal levels as seen with saline.
P30178
-47IN VIVO TESTING FOR ANXIOLYTIC ACTIVITY
1) Social Interaction
Rats (male, Sprague Dawleys, Charles River, 250-300g) were housed in groups of eight in a holding room for 5 days. They were then housed singly in a room adjacent to the experimental room for 4 days prior to the experimental day. On the experimental day rats were administered vehicle El or a benzodiazepine anxiolytic, chlordiazepoxide, s.c. in pairs (n=8-16), at 15 minute intervals beginning at 10.00 a.m. 30 mins, later they were placed with a weight matched pair-mate (encountered for the first time) in the social interaction box in a separate room. The box was made of white perspex 54 cm x 37 cm x 26 cm with a transparent perspex front side and no lid. The floor was divided up into 24 squares and the box was brightly lit (115 lux). Active social interactive behaviours (grooming, sniffing, climbing over or under, following, biting, mounting and boxing) were scored blind for the next 15 min by remote video monitoring to give total interaction scores. The number of squares crossed by each rat was also scored and summed. After the end of each test the box was carefully wiped.
ζ El increased total interaction scores over the dose range 0.001 - 1.0 mg/kg
S.C. Locomotion scores were not significantly altered although a trend ( 25 towards reduced locomotion was seen at 10.0 mg/kg S.C. This profile is consistent with anxiolysis.
2) X-Maze
The X-maze was raised 50 cm above the floor and consisted of two enclosed arms 45 cm (long) x 10 cm (wide) and 10 cm (high) and two open arms 45 x 10 x 1 cm, arranged such that the two arms of each type were opposite each other. Both arm types were marked into two equal sections. Rats were placed onto the centre of the X-maze and observed for a period of five min during which time the following parameters were recorded: 1) The number of entries on to, and the time spent on, (a) open arms (b) closed arms, (c) end of open arms and (d) end of closed arms. 2) the number of sections crossed. The fear drive evoked in the open arms
P30178
-48exceeds that in the closed arms and rats typically show a clear preference for the enclosed arms. Anxiolytic drugs increase the number of entries made onto, and the time spent on, the outer half of the open arms, and also the percentage of entries made onto, and the time spent on, the whole of the open arms. These four measures of anxiety, and also the total number of sections traversed, were calculated for each animal.
At doses between 0.01 and 1.0 mg/kg s.c., El increased measures of anxiolysis (time spent on open arm, entries to end of open arm, % time on open arm and % entries onto open arm), without affecting locomotion over ( a five minute period. The most consistently affected measure was % time on the open arm. This profile of action is consistent with anxiolysis and Λ was mirrored by the positive control, chlordiazepoxide (5 mg/kg s.c.).
IN VIVO TESTING FOR ANTIEMETIC ACTIVITY
Ferrets were dosed lOgg kgl p.o., 15 min before total body irradiation 20 (Bermudez et al, Br J. Cancer 1988, 58, p644)
MEAN NO. VOMITS MEAN NO. RETCHES
Control 14 ± 1.6 120.3 ± 16.1 n=8
El 6.3 ±1.6 81.5 ±11.6
Data: Mean ± sem
P30178 U(JW. pa|
4*.erta»ocd r.·. •hat manner part’-f.'l.rly desenbefl and

Claims (21)

1. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:
R.
R:
(I) in which Xi-(CH2)x-X2 forms a 5-7 membered ring wherein:
Xl is O or S;
X2 is O, S, NR or NRCO wherein R is hydrogen or Ci.g alkyl; x is 1, 2 or 3;
Rl is hydrogen, amino, halo, Cj.g alkyl, hydroxy or Ci.g alkoxy; R2 is hydrogen, halo, Ci.g alkyl, Ci.g alkoxy, nitro, amino or Cj.g alkylthio;
R3 is hydrogen, halo, Ci.g alkyl, Ci.g alkoxy or amino;
R4 and R5 are independently hydrogen or Ci.g alkyl; YisOorNH;
Z is of sub-formula (a), (b) or (c):
‘a (a) (b)
-<CH2)n3 —N
Re
R.
(c)
P30178
-50wherein
-(Cl^n1 is attached at carbon or nitrogen and nl is 1, 2, 3 or 4; n^ is 1 or 2; n^ is 2, 3, 4 or 5;
5 q is 0,1, 2 or 3; p is 0,1 or 2; m is 0,1 or 2;
Ra is hydrogen or a lipophilic group, such as Cj_i2 alkyl or aralkyl;
Rg, R7 and Rg are independently hydrogen or Cj.g alkyl; and R9 is hydrogen or Ci. 10 alkyl;
or a compound of formula (I) wherein the CO-Y linkage is replaced by a
10 heterocyclic bioisostere;
in the manufacture of a medicament for use as a 5-HT4 receptor antagonist.
2. A use according to claim 1 wherein Rj is hydrogen or amino.
3. A use according to claim 1 or 2 wherein R2 is hydrogen or halo.
4. A use according to claim 1, 2, or 3 wherein R3 is hydrogen or halo.
20
5. A use according to any one of claims 1 to 4 wherein the disubstituent containing and X2 is Xi-(CH2)x-X2> including O-(CH2)2-O, O-(CH2)3-O, O-CH2-O, O-(CH2)2-NR4, O-(CH2)2-S or O-CH2-CONR4, or the disubstituent is O-C(CH3)2-O.
25
6. A use according to claim 5 wherein the disubstituent is
O-(CH2)2-O.
7. A use according to any one of claims 1 to 6 wherein Y is O.
30
8. A use according to any one of claims 1 to 7 wherein Z is of sub-formula (a) and (0¾)^ is attached at a carbon atom of the azacycle.
9. A use according to claim 8 wherein Z is N-substituted 4-piperidylmethyl.
10. A use according to claim 9 wherein the N-substituent is C3 or greater alkyl, or optionally substituted benzyl.
P30178
-5111. Novel compounds of formula (I), and pharmaceutically acceptable salts thereof, as defined in claims 1 lo 10.
12. A compound according to claim 11, as described with reference to any one of the Examples.
13. A compound selected from El to E54 inclusive, in free base form, or as a pharmaceutically acceptable salt.
14. A process for preparing the ester or amide compounds according to claim 11,12 or 13, which comprises reacting an appropriate benzoic acid derivative with an appropriate alcohol or amine.
15. 8-Aniini)-7-ehlero-l,4-benzuiliuxan-5-caibuxylie acid Or a reactive derivative thereof.
16. A pharmaceutical composition comprising a compound according to any one of claims 11,12 or 13, and a pharmaceutically acceptable carrier.
17. A compound according to any one of claims 11, 12 or 13, for use in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
18. A compound according to claim 17, for use in the treatment of irritable bowel syndrome.
19. A compound according to claim 17, for use in the treatment of the nausea and gastric symptoms ofgastro-oesophagal reflux disease and dyspepsia.
20. A compound according to claim 17, for use in the treatment of atrial arrhythmias and etroko.
21. A compound according to claim 17, for use in the treatment of anxiety.
22. A compound according to claim 17, for use in the treatment of migraine.
APAP/P/1992/000422A 1991-09-14 1992-09-10 Compounds having 5TH4 receptor antagonist activity. AP373A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919119692A GB9119692D0 (en) 1991-09-14 1991-09-14 Pharmaceuticals
GB929202510A GB9202510D0 (en) 1992-02-06 1992-02-06 Pharmaceuticals

Publications (2)

Publication Number Publication Date
AP9200422A0 AP9200422A0 (en) 1992-10-31
AP373A true AP373A (en) 1994-12-07

Family

ID=26299541

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1992/000422A AP373A (en) 1991-09-14 1992-09-10 Compounds having 5TH4 receptor antagonist activity.

Country Status (4)

Country Link
CN (1) CN1040436C (en)
AP (1) AP373A (en)
IL (1) IL103138A (en)
MA (1) MA22647A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618967D0 (en) * 1996-09-11 1996-10-23 Smithkline Beecham Plc Pharmaceuticals
WO2002011766A2 (en) * 2000-08-07 2002-02-14 Laboratoire Glaxosmithkline S.A.S. Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
ITMI20031468A1 (en) * 2003-07-18 2005-01-19 Acraf ATIVE DRUG IN NEUROPATHIC PAIN
CN103420989B (en) * 2012-05-15 2016-03-23 华中科技大学 Benzodioxane derivative and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2396757A2 (en) * 1977-07-08 1979-02-02 Ile De France Psycho-functional alkylene bis:oxy benzamide cpds. - useful in gastroenterology, cardiology, urology, rheumatology and gynaecology
GB2176785A (en) * 1985-06-19 1987-01-07 Astra Laekemedel Ab Annellated benzamide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888353A (en) * 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
FR2593504B1 (en) * 1986-01-30 1988-12-09 Ile De France NOVEL DIHYDROBENZOFURANNE - AND CHROMANE - CARBOXAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS NEUROLEPTICS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2396757A2 (en) * 1977-07-08 1979-02-02 Ile De France Psycho-functional alkylene bis:oxy benzamide cpds. - useful in gastroenterology, cardiology, urology, rheumatology and gynaecology
GB2176785A (en) * 1985-06-19 1987-01-07 Astra Laekemedel Ab Annellated benzamide derivatives

Also Published As

Publication number Publication date
CN1073173A (en) 1993-06-16
AP9200422A0 (en) 1992-10-31
MA22647A1 (en) 1993-04-01
IL103138A (en) 1999-05-09
CN1040436C (en) 1998-10-28
IL103138A0 (en) 1993-02-21

Similar Documents

Publication Publication Date Title
EP0604494B1 (en) 5-ht4 receptor antagonists
AP401A (en) Condensed indole derivatives as 5H4-receptor antagonists.
NZ243993A (en) Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
EP0667867A1 (en) Piperidine derivatives as 5-ht4 receptor antagonists
EP0625149A1 (en) Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
AU682317B2 (en) Heteroaryl compounds used as pharmaceuticals
AP373A (en) Compounds having 5TH4 receptor antagonist activity.
WO1994029298A1 (en) 8-amino-7-chloro-1,4-benzodioxan-5-carboxylic acid, -1-butyl-4-piperidinyl ester as a 5-ht4-receptor antagonist
AU668102C (en) 5-HT4 receptor antagonists
NZ271972A (en) Condensed indole derivatives and medicaments
RU2124512C1 (en) Heterocyclic compounds as antagonists of 5-ht4 receptors, method of synthesis, pharmaceutical composition
HK1023560B (en) N-(1-nbutyl-4-piperidyl)methyl-3,4-dihydro-2h-1,3 oxazino 3,2-a indole-10-carboxamide or a pharmaceutically acceptable salt thereof
HK1023560A1 (en) N-(1-nbutyl-4-piperidyl)methyl-3,4-dihydro-2h-1,3 oxazino 3,2-a indole-10-carboxamide or a pharmaceutically acceptable salt thereof
HK1012352B (en) Condensed indole derivatives as 5-ht4-receptor antagonists
PT100855B (en) The use of a bicyclic heterocyclic compound, in particular a benzodioxan derivative, for the preparation of a medicament